Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo-controlled phase 3 trial evaluating the safety of resmetirom in adults with nonalcoholic fatty liver disease and presumed NASH. Patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Stephen A., Taub, Rebecca, Neff, Guy W., Lucas, K. Jean, Labriola, Dominic, Moussa, Sam E., Alkhouri, Naim, Bashir, Mustafa R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667098/
https://www.ncbi.nlm.nih.gov/pubmed/37845512
http://dx.doi.org/10.1038/s41591-023-02603-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667098/
https://www.ncbi.nlm.nih.gov/pubmed/37845512
http://dx.doi.org/10.1038/s41591-023-02603-1

Ejemplares similares